KKR & Co agreed to acquire Prometic Bioseparations, a pharmaceutical company that develops therapeutic treatments and processes to separate biological material, from Liminal BioSciences, a clinical-stage biopharmaceutical company, for £45m. "We are very pleased to announce the initial transaction resulting from our ongoing strategic process that will further our transition to a new focus on our small molecule therapeutics division. The initial cash proceeds from the Proposed Sale will serve to strengthen our financial position, and the Company will have the opportunity to receive further potential cash payments based on the future performance of PBL's business," Kenneth Galbraith, Liminal BioSciences CEO.